We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LGN:NASDAQLegence Corp. Analysis

Data as of 2026-04-15 - not real-time

$66.06

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Legence Corp. (LGN) is trading well above its 20‑day (≈$56), 50‑day (≈$53) and 200‑day (≈$45) simple moving averages, signaling strong bullish momentum. The RSI sits near 70, indicating the stock is technically overbought, while the MACD line remains above its signal, reinforcing the bullish bias. However, the market price of $66.06 exceeds the discounted cash‑flow fair value of roughly $47, implying the equity is currently overvalued. Revenue growth of 34.6% is impressive, yet profitability is weak with a negative net margin and operating margin barely above 1%, and the balance sheet is strained by a debt‑to‑equity ratio over 120%. Volatility is elevated (≈58% 30‑day) and beta is high (≈2.5), suggesting the stock will continue to swing sharply.
The sector’s cyclical nature, combined with high leverage and modest cash reserves, heightens financial risk, while the company’s focus on sustainable building systems offers a compelling long‑term narrative. Investors should weigh the strong top‑line growth and technical upside against the overvaluation, thin margins, and heightened market risk before deciding on exposure.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (price above SMAs, MACD bullish)
  • RSI approaching overbought territory
  • Current overvaluation relative to DCF

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth trajectory
  • Persistently thin or negative profit margins
  • High leverage and elevated beta

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Stock priced well above fair value estimates
  • Debt‑heavy balance sheet limiting financial flexibility
  • High volatility and cyclical sector exposure

Key Metrics & Analysis

Financial Health

Revenue Growth34.60%
Profit Margin-2.34%
P/E Ratio47.9
ROE-15.58%
ROA2.38%
Debt/Equity121.11
P/B Ratio10.8
Op. Cash Flow$256.9M
Free Cash Flow$228.3M
Industry P/E31.2

Technical Analysis

TrendBullish
RSI69.6
Support$47.80
Resistance$67.10
MA 20$56.20
MA 50$53.34
MA 200$44.58
MACDBullish
VolumeIncreasing
Fear & Greed Index88.64

Valuation

Fair Value$47.17
Target Price$63.05
Upside/Downside-4.55%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.47
Volatility58.48%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.